TABLE I. Baseline Characteristics of Subjects Completing Lung Function Testing.

	All Subjects Completing Enrollment Lung Function Testing	Subjects Completing Enrollment and Follow-up Lung Function Testing	Subjects Completing only Enrollment Lung Function Testing
Subjects (n)	44	32	12
Gender (male)	29 (66%)	22 (69%)	7 (58%)
Race (Caucasian)	32 (73%)	26 (81%)	6 (50%)
Mean age at enrollment (months)*	15.7 ± 5.2	15.2 ± 4.9	15.5 ± 5.4
Eczema (physician-diagnosed and steroid treated)	16 (36%)	10 (31%)	6 (50%)
Family history asthma (1st degree relative)	23 (52%)	14 (44%)	9 (75)%
Enviromental tobacco smoke exposure	12 (27%)	9 (28%)	3 (25%)
Prior treatment with systemic steroids for wheezing	33 (75%)	25 (78%)	8 (67%)
History of ED visit for wheezing	33 (75%)	24 (75%)	9 (75%)
History of hospitalization for wheezing	16 (36%)	10 (31%)	6 (50)%
History of wheezing apart from viral infections	16 (36%)	12 (38%)	4 (33%)
Enrollment SB-eNO (ppb)*	28.7 ppb ± 16.1	27.4 ppb ± 15.3	31.2± 19.5
Enrollment FVC (z-score)**	-0.04 (-0.42 to 0.35)	-0.01 (-0.51 to 0.49)	-0.24 (-0.65 to 0.17)
Enrollment FEV0.5 (z-score)**	-0.42 (-0.78 to -0.07)	-0.41 (-0.80 to -0.04)	-0.21 (-0.46 to -0.05)
Enrollment FEF25-75 (z-score)**	-0.67 (-1.10 to -0.25)	-0.82 (-1.33 to -0.30)	-0.45 (-1.15 to 0.27)
Enrollment FEF75 (z-score)**	-0.72 (-1.14 to -0.31)	-0.84 (-1.31 to -0.43)	-0.56 (-1.22 to -0.12)

Definition of Abbreviations: SB-eNO = single-breath exhaled nitric oxide; ED = emergency department.

^*Data are presented as the mean ± SD

^**Data are presented as the mean ± 95% CI